| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -2.9 | -3.5 |
| EPS (diluted, $ a share) | $-0.02 | $-0.02 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, IMR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Imricor Medical Systems, Inc.: key numbers
- Shares outstanding
- 358.66MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Imricor Medical Systems, Inc.
All →Imricor Medical Systems Financial Results
Imricor Medical Systems reported Q3 2026 financial results, highlighted by a 437% year-over-year revenue increase to $188k as the company commenced its U.S. commercial launch. The company secured its first two U.S. hospital customers, Rady Children’s Hospital–San Diego and Children’s Medical Center Dallas, for its NorthStar system and established a strategic partnership with Philips for a turnkey cardiac iMR lab solution.
- Term
- Q3 2026
“The third quarter of 2026 is the quarter our U.S. commercial launch became real. Within weeks of launching Imricor Cardiovascular, two of the nation’s leading children’s hospitals, Rady Children’s Hospital in San Diego and Children’s Medical Center Dallas, committed to NorthStar to deliver completely radiation-free cardiac catheterisation for their patients.”
Steve Wedan, Executive Chair, President and CEO
“Children who need multiple heart procedures over their lives should not have to carry a lifetime of radiation exposure. The U.S. launch is where we begin to change that”
Steve Wedan, Executive Chair, President and CEO